E

Enzymatica AB (publ)
STO:ENZY

Watchlist Manager
Enzymatica AB (publ)
STO:ENZY
Watchlist
Price: 3 SEK 2.39% Market Closed
Market Cap: 728.2m SEK

EV/EBIT
Enterprise Value to EBIT

-12.8
Current
-10.2
Median
16.3
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-12.8
=
Enterprise Value
662.3m SEK
/
EBIT
-51.6m SEK
EBIT Growth EV/EBIT to Growth
SE
E
Enzymatica AB (publ)
STO:ENZY
Average EV/EBIT: 1 866.9
Negative Multiple: -12.8
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.4
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15.3
14%
1.1
CH
Roche Holding AG
SIX:ROG
11.2
6%
1.9
CH
Novartis AG
SIX:NOVN
13.8
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.5
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.1
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.3
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-12.7
2-Years Forward
EV/EBIT
-13
3-Years Forward
EV/EBIT
N/A